- Home
- AEON vs HIND Comparison
AEON vs HIND Comparison
Compare AEON & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEON | HIND |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 15.2M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AEON | HIND |
|---|---|---|
| Price | $0.23 | $1.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $1.82 | ★ $8.83 |
| AVG Volume (30 Days) | ★ 1.3M | 16.1K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $82.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $0.18 | $1.75 |
| 52 Week High | $1.45 | $6.56 |
Technical Indicators
Market Signals| Indicator | AEON | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 42.42 |
| Support Level | $0.18 | $1.82 |
| Resistance Level | $0.33 | $2.31 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 8.72 | 37.50 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.